Octamers and nanoparticles as hemoglobin based blood substitutes

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1784, Issue 10, 2008, Pages 1448-1453

  Baudin Creuza, Véronique ^a   Chauvierre, Cédric ^a   Domingues, Elisa ^a   Kiger, Laurent ^a   Leclerc, Liliane ^a   Vasseur, Corinne ^a   Célier, Chantal ^a   Marden, Michael C ^a  

^a INSERM   (France)

Author keywords

Cooperativity; Hemoglobin octamer; Nanoparticle; Oxidation

Indexed keywords

BLOOD SUBSTITUTE; HAPTOGLOBIN; LIPOSOME; NANOPARTICLE; OCTAMER; POLYMER; RECOMBINANT HEMOGLOBIN; UNCLASSIFIED DRUG;

BLOOD TRANSFUSION; DRUG PROTEIN BINDING; HUMAN; NANOTECHNOLOGY; NONHUMAN; OLIGOMERIZATION; OXIDATION; OXYGEN AFFINITY; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW;

BIOLOGICAL TRANSPORT; BLOOD SUBSTITUTES; GENETIC ENGINEERING; GENETIC VECTORS; GLOBINS; HAPTOGLOBINS; HEMOGLOBINS; HUMANS; KINETICS; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS; POLYSACCHARIDES; RECOMBINANT PROTEINS;

EID: 52049100824     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2008.02.005     Document Type: Review

References (74)

1. Zauder H.L., and Stehling L. NATA Textbook Transfusion Medicine and Alternatives to Blood Transfusion, Chapter I: History and Development of Transfusion Medicine. In: R J (Ed). Network for Advanced Transfusion Alternatives (2000)
2. Marden M.C., Kiger L., Poyart C., Rashid A.K., Kister J., Stetzkowski-Marden F., Caron G., Haque M., and Moens L. Modulation of the oxygen affinity of cobalt-porphyrin by globin. FEBS Lett. 472 (2000) 221-224
3. Olson J.S., Eich R.F., Smith L.P., Warren J.J., and Knowles B.C. Protein engineering strategies for designing more stable hemoglobin-based blood substitutes. Artif. Cells, Blood Substit. and Immob. Biotech. 251 (1997) 227-241
4. Marden M.C., Griffon N., and Poyart C. Oxygen delivery and autoxidation of hemoglobin. J. Societé Française Transfusion Sanguine/TCB 6 (1995) 473-480
5. Chatterjee R., Welty E.V., Walder R.Y., Pruitt S.L., Rogers P.H., Arnone A., and Walder J.A. Isolation and characterization of a new hemoglobin derivative cross-linked between the alpha chains (lysine 99 alpha 1 → lysine 99 alpha 2). J. Biol. Chem. 261 (1986) 9929-9937
6. Looker D., Abbott-Brown D., Cozart P., Durfee S., Hoffman S., Mathews A.J., Miller-Roehrich J., Shoemaker S., Trimble S., Fermi G., Komiyama N.H., Nagai K., and Stetler G.L. A human recombinant haemoglobin designed for use as a blood substitute. Nature 35 (1992) 258-260
7. Tsai A.G., Cabrales P., Manjula B.N., Acharya S.A., Winslow R.M., and Intaglietta M. Dissociation of local nitric oxide concentration and vasoconstriction in the presence of cell-free haemoglobin oxygen carriers. Blood 108 (2006) 3603-3610
8. Moore E.E., Johnson J.L., Cheng A.M., Masumo T., and Banerjee A. Insights from studies of blood substitutes in trauma. Shock 24 (2005) 197-205
9. Haney C.R., Buehler P.W., and Gulati A. Purification and chemical modifications of hemoglobin in developing hemoglobin based oxygen carriers. Adv. Drug Delivery Rev. 40 (2000) 153-169
10. Dull R.O., DeWitt B.J., Dinavahi R., Schwartz L., Hubert C., Pace N., and Fronticelli C. Quantitative assessment of hemoglobin-induced endothelial barrier dysfunction. J. Appl. Physiol. 97 (2004) 1930-1937
11. Jahr J.S., Walker V., and Manoochehri K. Blood substitutes as pharmacotherapies in clinical practice. Curr. Opin. Anaesthesiol. 20 (2007) 325-330
12. Winslow R.M. Red cell substitutes. Semin. Hematol. 44 (2007) 51-59
13. Hirsch R.E., Jelicks L.A., Wittenberg B.A., Kaul D.K., Shear H.L., and Harrington J.P. A first evaluation of the natural high molecular weight polymeric Lumbricus terrestris hemoglobin as an oxygen carrier. Artif. Cells Blood Substit. Immob. Biotechnol. 25 (1997) 429-444
14. Fronticelli C., Arosio D., Bobofchak K.M., and Vasquez G.B. Molecular engineering of a polymer of tetrameric hemoglobins. Proteins 44 (2001) 212-222
15. Bobofchak K.M., Mito T., Texel S.J., Bellelli A., Nemoto M., Traystman R.J., Koehler R.C., Brinigar W.S., and Fronticelli C. A recombinant polymeric hemoglobin with conformational, functional, and physiological characteristics of an in vivo O2 transporter. Am. J. Physiol. Heart Circ. Physiol. 285 (2003) 549-561
16. Fablet C., Marden M.C., Green B.N., Ho C., Pagnier J., and Baudin-Creuza V. Stable octameric structure of recombinant hemoglobin alpha(2)beta(2)83 Gly ® Cys. Protein Sci. 12 (2003) 690-695
17. Vasseur-Godbillon C., Sahu S.C., Domingues E., Fablet C., Giovannelli J.L., Tam T.C., Ho N.T., Ho C., Marden M.C., and Baudin-Creuza V. Recombinant hemoglobin βG83C-F41Y: an octameric protein. FEBS J. 273 (2006) 230-241
18. Chang T.M.S., and Yu W.P. In: Chang T.M.S. (Ed). Blood Substitutes: Principles, Methods, Products and Clinical Trials, Chapter 11, Nanoencapsulation of Hemoglobin and Red Blood Cell Enzymes Based on Nanotechnology and Biodegradable Polymer (1998), Karger Landes Systems
19. Zhao J., Liu C.S., Yuan Y., Tao X.Y., Shan X.Q., Sheng Y., and Wu F. Preparation of hemoglobin-loaded nano-sized particles with porous structure as oxygen carriers. Biomaterials 28 (2007) 1414-1422
20. Dieryck W., Pagnier J., Poyart C., Marden M.C., Gruber V., Bournat P., Baudino S., and Merot B. Human haemoglobin from transgenic tobacco. Nature 386 (1997) 29-30
21. Baudin V., Pagnier J., Lacaze N., Bihoreau M.T., Kister J., Marden M.C., Kiger L., and Poyart C. Allosteric properties of haemoglobin β41(C7) Phe → Tyr: a stable, low oxygen affinity variant synthesized in Escherichia coli. Bioch. Biophys. Acta 1159 (1992) 223-226
22. Shen T.J., Ho N.T., Zou M., Sun D.P., Cottam P.F., Simplaceanu V., Tam M.F., Bell D.A., and Ho C. Production of human normal adult and fetal hemoglobins in Escherichia coli. Protein Eng. 10 (1997) 1085-1097
23. Vasseur-Godbillon C., Hamdane D., Marden M.C., and Baudin-Creuza V. High-yield expression in Escherichia coli of soluble human α-hemoglobin complexed with its molecular chaperone. Protein Eng. Des. Sel. 19 (2006) 91-97
24. Kihm A.J., Kong Y., Hong W., Russel J.E., Rouda S., Adachi K., Simon M.C., Blobel G.A., and Weiss M.J. An abundant erythroid protein that stabilizes free α-haemoglobin. Nature 417 (2002) 758-763
25. Studier W.F. Protein production by auto-induction in high density shaking cultures. Protein Expr. Purif. 41 (2005) 207-234
26. Nagel R.L., and Gibson Q.H. The binding of hemoglobin to haptoglobin and its relation to subunit dissociation of haemoglobin. J. Biol. Chem. 246 (1971) 69-73
27. Wada T., Oara H., Watanabe K., Kinoshita H., and Yachi A. Autoradiographic study on the site of uptake of the haptoglobin-hemoglobin complex. J. Reticuloendothel. Soc. 8 (1970) 185-193
28. Kristiansen M., Graversen J.H., Jacobsen C., Sonne O., Hoffman H.J., Law S.K., and Moestrup S.K. Identification of the haemoglobin scavenger receptor. Nature 409 (2001) 198-201
29. Schaer D.J., Schaer C.A., Buehler P.W., Boykins R.A., Schoedon G., Alayash A.I., and Schaffner A. CD163 is the macrophage scavenger receptor for native and chemically modified hemoglobins in the absence of haptoglobin. Blood 107 (2006) 373-380
30. Puisieux F., and Roblot-Treupel L. Vectorisation et vecteurs de médicaments. STP Pharma. Sci. 5 (1989) 107-113
31. Gregoriadis G. Drug entrapment in liposomes. FEBS Lett. 36 (1973) 292-296
32. Kreuter J., and Speiser P. In vitro studies of poly(methyl methacrylate) adjuvants. J. Pharm. Sci. 65 (1976) 1624-1627
33. Couvreur P., Kante B., Roland M., Guiot P., Bauduin P., and Speiser P. Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties. J. Pharm. Pharmacol. 31 (1979) 331-332
34. Vauthier C., Dubernet C., Fattal E., Pinto-Alphandary H., and Couvreur P. Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv. Drug Delivery Rev. 55 (2003) 519-548
35. Lenaerts V., Couvreur P., Chritiaens-Leyh D., Joiris E., Roland M., Rollman B., and Speiser P. Degradation of poly (isobutyl cyanoacrylate) nanoparticles. Biomaterials, 5 (1984) 65-68
36. Kattan J., Droz J.P., Couvreur P., Marino J.P., Boutan-Laroze A., Rougier P., Brault P., Vranckx H., Grognet J.M., Morge X., and Sancho-Garnier H. Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles. Invest. New Drugs 10 (1992) 191-199
37. Li Y.P., Pei Y.Y., Zhou Z.H., Zhang X.Y., Gu Z.H., Ding J., Zhou J.J., Gao X.J., and Zhu J.H. Stealth polycyanoacrylate nanoparticles as tumor necrosis factor-a carriers: pharmacokinetics and anti-tumor effects. Biol. Pharm. Bull. 24 (2001) 662-665
38. Chiannilkulchai N., Ammoury N., Caillou B., Devisaguet J.P., and Couvreur P. Hepatic tissue distribution of doxorubicin-loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metastasis-bearing mice. Cancer Chemother. Pharmacol. 26 (1990) 122-126
39. Cuvier C., Roblot-Treupel L., Millot J.M., Lizard G., Chevillard S., Manfait M., Couvreur P., and Poupon M.F. Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. Biochem. Pharmacol. 44 (1992) 509-517
40. Soma C.E., Dubernet C., Barratt G., Benita S., and Couvreur P. Investigation of the role of macrophages on the cytotoxicity of doxorubicin and doxorubicin-loaded nanoparticles on M5076 cells in vitro. J. Control. Release 68 (2000) 283-289
41. Fattal E., Youssef M., Couvreur P., and Andremont A. Treatment of experimental salmonellosis in mice with ampicillin-bound nanoparticles. Antimicrob. Agents Chemother. 33 (1989) 1540-1543
42. Balland O., Pinto-Alphandary H., Pecquet S., Andremont A., and Couvreur P. The uptake of ampicillin-loaded nanoparticles by murine macrophages infected with Salmonella typhimurium. J. Antimicrob. Chemother. 33 (1994) 509-522
43. Schwab G., Chavany C., Duroux I., Goubin G., Lebeau J., Helene C., and Saison-Behmoaras T. Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 10460-10464
44. Lambert G., Bertrand J.R., Fattal E., Subra F., Pinto-Alphandary H., Malvy C., Auclair C., and Couvreur P. EWS fli-1 antisense nanocapsules inhibit Ewing sarcoma-related tumor in mice. Biochem. Biophys. Res. Commun. 279 (2000) 401-406
45. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Delivery Rev. 47 (2001) 65-81
46. Calvo P., Gouritin B., Villarroya H., Eclancher F., Giannavola C., Klein C., Andreux J.P., and Couvreur P. Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur. J. Neurosci. 15 (2002) 1317-1326
47. Couvreur P., Barratt G., Fattal E., Legrand P., and Vauthier C. Nanocapsule technology: a review. Crit. Rev. Drug Deliv. Syst. 19 (2002) 99-134
48. Vittaz M., Bazile D., Spenlehauer G., Verrecchia T., Veillard M., Puisieux F., and Couvreur P. Effect of PEO surface density on long circulating PLA-PEO nanoparticles which are very low complement activators. Biomaterials 17 (1996) 1575-1581
49. Sahli H., Tapon-Bretaudière J., Fischer A.M., Sternberg C., Spenlehauer G., Verrecchia T., and Labarre D. Interactions of poly(lactic acid) and poly(lactic acid-co-ethylene oxide) nanoparticles with the plasma factors of the coagulation system. Biomaterials 18 (1997) 281-288
50. Gref R., Minamitake Y., Peracchia M.T., Trubetskoy V., Torchilin V., and Langer R. Biodegradable long-circulating polymeric nanospheres. Science 263 (1994) 1600-1603
51. Bazile D., Prud'homme C., Bassoulet M.T., Marlard M., Spenlehauer G., and Veillard M. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J. Pharm. Sci. 84 (1995) 493-498
52. Peracchia M.T., Vauthier C., Passirani C., Couvreur P., and Labarre D. Complement consumption by poly(ethylene glycol) in different conformations chemically coupled to poly(isobutyl 2-cyanoacrylate) nanoparticles. Life Sci. 61 (1997) 749-761
53. Peracchia M.T., Fattal E., Desmaële D., Besnard M., Noël J.P., Gomis J.M., Appel M., D'Angelo J., and Couvreur P. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J. Control. Release 60 (1999) 121-128
54. Wu J., Akaike T., and Maeda H. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res. 58 (1998) 159-165
55. Maeda H., Wu J., Tanaka S., and Akaike T. In: Pitt C. (Ed). Ninth International Symposium on Recent Advances in Drug Delivery Systems (1999), Elsevier Scientific Publications, Shannon 114
56. Ranney D.F. Biomimetic transport and rational drug delivery. Biochem. Pharmacol. 59 (2000) 105-114
57. Maruyama K., Ishida O., Takizawa T., and Moribe K. Possibility of active targeting to tumor tissues with liposomes. Adv. Drug Delivery Rev. 40 (1999) 89-102
58. Mastrobattista E., Koning G.A., and Storm G. Immunoliposomes for the targeted delivery of antitumor drugs. Adv. Drug Delivery Rev. 40 (1999) 103-127
59. Stella B., Arpicco S., Peracchia M.T., Desmaële D., Hoebeke J., Renoir M., D'Angelo J., Cattel L., and Couvreur P. Design of folic acid-conjugated nanoparticles for drug targeting. J. Pharm. Sci. 89 (2000) 1452-1464
60. Gregoriadis G., McCormack B., Wang Z., and Lifely R. Polysialic acids: potential in drug delivery. FEBS Lett. 315 (1993) 271-276
61. Olivier J.C., Vauthier C., Taverna M., Ferrier D., and Couvreur P. Preparation and characterization of biodegradable poly(isobutylcyano acrylate) nanoparticles with the surface modified by the adsorption of proteins. Colloids Surf., B Biointerfaces 4 (1995) 349-356
62. Olivier J.C., Vauthier C., Taverna M., Puisieux F., Ferrier D., and Couvreur P. Stability of orosomucoid-coated poly(isobutylcyanoacrylate) nanoparticles in the presence of serum. J. Control. Release 40 (1996) 157-168
63. Passirani C., Barratt G., Devissaguet J.P., and Labarre D. Interactions of nanoparticles bearing heparin or dextran covalently bound to poly(methylmethacrylate) with the complement system. Life Sci. 62 (1998) 775-785
64. Passirani C., Barratt G., Devissaguet J.P., and Labarre D. Long-circulating nanopartides bearing heparin or dextran covalently bound to poly(methyl methacrylate). Pharm. Res. 15 (1998) 1046-1050
65. Chauvierre C., Labarre D., Couvreur P., and Vauthier C. Radical emulsion polymerization of alkylcyanoacrylates initiated by the redox system dextran-cerium(IV) under acidic aqueous conditions. Macromolecules 36 (2003) 6018-6027
66. Chauvierre C., Labarre D., Couvreur P., and Vauthier C. Plug-in spectrometry with optical fibers as a novel analytical tool for nanoparticles technology: application to the investigation of the emulsion polymerization of the alkylcyanoacrylate. J. Nanopart. Res. 5 (2003) 365-371
67. Chauvierre C., Labarre D., Couvreur P., and Vauthier C. Novel polysaccharide-decorated poly(isobutyl cyanoacrylate) nanoparticles. Pharm. Res. 20 (2003) 1786-1793
68. Chauvierre C., Labarre D., Couvreur P., and Vauthier C. A new approach for the characterization of insoluble amphiphilic copolymers based on their emulsifying properties. Colloid Polym. Sci. (Internet) 282 (2004) 1097-1104
69. Chauvierre C., Labarre D., Couvreur P., and Vauthier C. Evaluation of the surface properties of dextran-coated poly(isobutylcyanoacrylate) nanoparticles by spin-labelling coupled with electron resonance spectroscopy. Colloid Polym. Sci. (Internet) 282 (2004) 1016-1025
70. Labarre D., Vauthier C., Chauvierre C., Petri B., Müller R., and Chehimi M.M. Interactions of blood proteins with poly(isobutylcyanoacrylate) nanoparticles decorated with a polysaccharidic brush. Biomaterials 26 (2005) 5075-5084
71. Chauvierre C., Vauthier C., Labarre D., Couvreur P., Marden M.C., and Leclerc L. A new generation of polymer nanoparticles for drug delivery. Cell. Mol. Biol. 50 (2004) 233-239
72. Chauvierre C., Marden M.C., Vauthier C., Labarre D., Couvreur P., and Leclerc L. Heparin coated poly(alkylcyanoacrylate) nanoparticles coupled to haemoglobin: a new oxygen carrier. Biomaterials 25 (2004) 3081-3086
73. Chauvierre C., Leclerc L., Labarre D., Appel M., Marden M.C., Couvreur P., and Vauthier C. Enhancing the tolerance of poly(isobutylcyanoacrylate) nanoparticles with a modular surface design. Int. J. Pharm. 338 (2007) 327-332
74. Netzer W.J., and Hartl F.U. Recombination of protein domains facilitated by co-translational folding in eukaryotes. Nature 388 (1997) 343-349